Kearsley JH - Search Results

1

Proteomics for breast cancer urine biomarkers.

Beretov J, Wasinger VC, Graham PH, Millar EK, Kearsley JH, Li Y. Beretov J, et al. Among authors: kearsley jh. Adv Clin Chem. 2014;63:123-67. doi: 10.1016/b978-0-12-800094-6.00004-2. Adv Clin Chem. 2014. PMID: 24783353 Review.

2

Tear fluid protein biomarkers.

You J, Willcox MD, Madigan MC, Wasinger V, Schiller B, Walsh BJ, Graham PH, Kearsley JH, Li Y. You J, et al. Among authors: kearsley jh. Adv Clin Chem. 2013;62:151-96. doi: 10.1016/b978-0-12-800096-0.00004-4. Adv Clin Chem. 2013. PMID: 24772667

3

Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.

Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL. Millar EK, et al. Among authors: kearsley jh. J Clin Oncol. 2009 Oct 1;27(28):4701-8. doi: 10.1200/JCO.2008.21.7075. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720911 Clinical Trial.

4

Innovative biomarkers for prostate cancer early diagnosis and progression.

You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P, Li Y. You J, et al. Crit Rev Oncol Hematol. 2010 Jan;73(1):10-22. doi: 10.1016/j.critrevonc.2009.02.007. Crit Rev Oncol Hematol. 2010. PMID: 19328712 Review.

5

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.

Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, Nasser E, Capp A, Sutherland RL. Millar EK, et al. Among authors: kearsley jh. Br J Cancer. 2011 Jul 12;105(2):272-80. doi: 10.1038/bjc.2011.228. Epub 2011 Jun 28. Br J Cancer. 2011. PMID: 21712826 Free PMC article.

6

Cancer stem cells in prostate cancer chemoresistance.

Ni J, Cozzi P, Hao J, Duan W, Graham P, Kearsley J, Li Y. Ni J, et al. Curr Cancer Drug Targets. 2014;14(3):225-40. doi: 10.2174/1568009614666140328152459. Curr Cancer Drug Targets. 2014. PMID: 24720286

7

CD44 is a biomarker associated with human prostate cancer radiation sensitivity.

Xiao W, Graham PH, Power CA, Hao J, Kearsley JH, Li Y. Xiao W, et al. Among authors: kearsley jh. Clin Exp Metastasis. 2012 Jan;29(1):1-9. doi: 10.1007/s10585-011-9423-7. Epub 2011 Sep 28. Clin Exp Metastasis. 2012. PMID: 21953074

8

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.

Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, Kearsley JH, Li Y. Ni J, et al. Among authors: kearsley jh. Prostate. 2014 May;74(6):602-17. doi: 10.1002/pros.22775. Epub 2014 Feb 12. Prostate. 2014. PMID: 24615685

9

Malignant phyllodes tumours of the breast display increased stromal p53 protein expression.

Millar EK, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, Lee CS. Millar EK, et al. Among authors: kearsley jh. Histopathology. 1999 Jun;34(6):491-6. doi: 10.1111/j.1365-2559.1999.00666.x. Histopathology. 1999. PMID: 10383692

10

In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.

Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y. Hao J, et al. Among authors: kearsley jh. PLoS One. 2012;7(8):e40716. doi: 10.1371/journal.pone.0040716. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22870202 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters